



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/601,953	06/24/2003	Steven C. Quay	02-03US	6874
36814	7590	04/18/2006	EXAMINER	
NASTECH PHARMACEUTICAL COMPANY INC 3450 MONTE VILLA PARKWAY BOTHELL, WA 98021-8906			KOSAR, ANDREW D	
			ART UNIT	PAPER NUMBER
			1654	

DATE MAILED: 04/18/2006

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10601953	6/24/03	QUAY, STEVEN C.	02-03US

EXAMINER

Andrew D. Kosar

ART UNIT	PAPER
----------	-------

1654 20060414

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The reply filed on February 2, 2006 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s): While Applicant has elected a peptide and a biologically active agent, Applicant has not fully identified a single pharmaceutical composition where all components are specifically identified, especially since Applicant has elected "linking claims 1-47 and 82-92 insofar as these claims recite the invention to be examined." Applicant has not identified those components in the composition which are recited, e.g., in claims 17 and 32. Furthermore, Applicant is requested to indicate which claims specifically read upon the elected composition, as the elected invention VRIP does not encompass claims drawn only to variants/derivatives, nor does it encompass occludin, etc.. See 37 CFR 1.111. Since the above-mentioned reply appears to be *bona fide*, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Andrew D. Kosar whose telephone number is (571)272-0913. The examiner can normally be reached on Monday - Friday 8am-430pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on (571)272-0974. The fax phone number for the organization where this application or proceeding is assigned is (571)273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Andrew D. Kosar, Ph.D.
Andrew D. Kosar, Ph.D.
Art Unit 1654

Bruce Campell
BRUCE R. CAMPELL, PH.D.
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600